Effect of Antiresorptive Drugs on Oral Implant Therapy: A Systemic Review

Abstract Clinicians who practice implant dentistry are still concerned about the life and longevity of dental implants in patients who have used anti-resorptive drugs. The alveolar bone must undergo significant remodelling to prepare the bone and surrounding tissues for surgery. Furthermore, throughout and after the dental implant's osseointegration phase, the bone around the implant fixture continuously remodels. Anti-resorptive drugs can hinder osseointegration and even cause medication-related osteonecrosis of the jaw (MRONJ). These drugs are used to decrease bone remodelling. Specifically, Bisphosphonates (BPs) can negatively impact osteoclasts and predispose other cells, such as osteoblasts, vascular cells, and fibroblasts, to death. This disturbance may lead to soft tissue toxicity and hinder angiogenesis. Increased BP release from inflammation surrounding dental implants may result in postponed implant failure. This article delves further into how anti-resorptive medications affect oral implant therapy.